Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Westra, Tjalke A ^a   Stirbu Wagner, Irina ^b   Dorsman, Sara ^b   Tutuhatunewa, Eric D ^a   de Vrij, Edwin L ^a   Nijman, Hans W ^a   Daemen, Toos ^a   Wilschut, Jan C ^a   Postma, Maarten J ^c,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b NETHERLANDS INSTITUTE FOR HEALTH SERVICES RESEARCH   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d Department of Epidemiology ^*  (Netherlands)

Author keywords

Cervical cancer; Cost effectiveness; Cross protection; Genital warts; HPV vaccination; Pricing of vaccines

Indexed keywords

BIVALENT HUMAN PAPILLOMAVIRUS VACCINE; IMIQUIMOD; PODOPHYLLOTOXIN; QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER INCIDENCE; CHILD; COHORT ANALYSIS; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CROSS PROTECTION; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PAPILLOMAVIRUS INFECTION; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; SCHOOL CHILD; UTERINE CERVIX CANCER;

CONDYLOMATA ACUMINATA; COST-BENEFIT ANALYSIS; CROSS PROTECTION; FEMALE; HUMANS; MASS VACCINATION; MODELS, ECONOMIC; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; UTERINE CERVICAL NEOPLASMS;

EID: 84873392886     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-75     Document Type: Article

References (34)

1. Scarinci IC, Garcia FA, Kobetz E, Partridge EE, Brandt HM, Bell MC, Dignan M, Ma GX, Daye JL, Castle PE. Cervical cancer prevention: new tools and old barriers. Cancer 2010, 116(11):2531-2542. 2876205, 20310056.
2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370(9590):890-907. 10.1016/S0140-6736(07)61416-0, 17826171.
3. Chan PK, Luk AC, Luk TN, Lee KF, Cheung JL, Ho KM, Lo KK. Distribution of human papillomavirus types in anogenital warts of men. J Clin Virol 2009, 44(2):111-114. 10.1016/j.jcv.2008.11.001, 19097933.
4. Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374(9686):301-314. 10.1016/S0140-6736(09)61248-4, 19586656.
5. Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199(7):936-944. 10.1086/597309, 19236277.
6. Szarewski A. Prophylactic HPV vaccines. Eur J Gynaecol Oncol 2007, 28(3):165-169.
7. van den Broek IV, Verheij RA, van Dijk CE, Koedijk FD, van der Sande MA, van Bergen JE. Trends in sexually transmitted infections in the Netherlands, combining surveillance data from general practices and sexually transmitted infection centers. BMC Fam Pract 2010, 11:39. 10.1186/1471-2296-11-39, 2886004, 20487552.
8. Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, Berkhof J. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011, 22(4):505-515. 10.1097/EDE.0b013e31821d107b, 21540743.
9. Coupe VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer 2009, 124(4):970-978. 10.1002/ijc.24000, 19035448.
10. de Kok IM, van Ballegooijen M, Habbema JD. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Canc Inst 2009, 101(15):1083-1092.
11. Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009, 27(35):4776-4783. 10.1016/j.vaccine.2009.05.085, 19539578.
12. Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ, Wilschut JC. Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses. J Infect Dis 2011, 204(3):377-384. 10.1093/infdis/jir281, 21742836.
13. Westra TA, Daemen T, Postma MJ, Wilschut JC. [Efficiency of human papillomavirus vaccination-estimates based on Dutch cost effectiveness analyses]. Ned Tijdschr Geneeskd 2009, 153:A356.
14. Insinga RP, Dasbach EJ, Elbasha EH. Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model. BMC Infect Dis 2009, 9:119. 10.1186/1471-2334-9-119, 2728100, 19640281.
15. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen-Daalmeijer N, Meijer CJ. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000, 87(2):221-227. 10.1002/1097-0215(20000715)87:2<221::AID-IJC11>3.0.CO;2-2, 10861478.
16. Lenselink CH, Melchers WJ, Quint WG, Hoebers AM, Hendriks JC, Massuger LF, Bekkers RL. Sexual behaviour and HPV infections in 18 to 29 year old women in the pre-vaccine era in the Netherlands. PLoS One 2008, 3(11):e3743. 10.1371/journal.pone.0003743, 2581437, 19011683.
17. Kramer M, Mollema L, Smits G, Boot H, de Melker H, der Klis FV. Age-specific HPV seroprevalence among young females in The Netherlands. Sex Transm Infect 2010, 86(7):494-499. 10.1136/sti.2009.041210, 20519252.
18. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2012, 343:d5775.
19. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Guideline for costing research, methods and standardized prices for economic evaluations in health care 2004, Diemen: Health Care Insurance Board.
20. Woodhall SC, Jit M, Cai C, Ramsey T, Zia S, Crouch S, Birks Y, Newton R, Edmunds WJ, Lacey CJ. Cost of treatment and QALYs lost due to genital warts: data for the economic evaluation of HPV vaccines in the United Kingdom. Sex Transm Dis 2009, 36(8):515-521. 10.1097/OLQ.0b013e3181a74c2c, 19543143.
21. Woodhall S, Ramsey T, Cai C, Crouch S, Jit M, Birks Y, Edmunds WJ, Newton R, Lacey CJ. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect 2008, 84(3):161-166. 10.1136/sti.2007.029512, 18339658.
22. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Canc Inst 2010, 102(5):325-339.
23. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Canc 2009, 19(7):1166-1176.
24. Malagon T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12(10):781-789. 10.1016/S1473-3099(12)70187-1, 22920953.
25. David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009, 115(3 Suppl):S1-S6.
26. Pharmacoeconomic guidelines around the world. The Internaltional Society of Pharmacoeconomics and Outcomes Research http://www.ispor.org/peguidelines/index.asp [accessed April 2011], Pharmacoeconomic guidelines around the world. The Internaltional Society of Pharmacoeconomics and Outcomes Research.
27. Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5(10):705-719. 10.4161/hv.5.10.9518, 19684472.
28. Beutels P, Scuffham PA, MacIntyre CR. Funding of drugs: do vaccines warrant a different approach?. Lancet Infect Dis 2008, 8(11):727-733. 10.1016/S1473-3099(08)70258-5, 18992409.
29. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. PharmacoEconomics 2011, 29(5):371-386. 10.2165/11539960-000000000-00000, 21504239.
30. Postma MJ. Dynamic modeling for pandemic influenza. Expet Rev Vaccine 2012, 11(5):543-546.
31. Morris SR. HPV vaccine strategies: the cost of HPV and the choice of vaccine. Sex Transm Infect 2009, 85(5):315-316. 10.1136/sti.2008.034793, 19773455.
32. Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011, 343:d5775. 10.1136/bmj.d5775, 3181234, 21951758.
33. Jit M, Choi YH, Edmunds WJ. Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 2008, 337:a769. 10.1136/bmj.a769, 2500202, 18640957.
34. Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Health 2012, 15(5):622-631. 10.1016/j.jval.2012.02.012, 22867770.